Encephalitis, Tick-Borne clinical trials
The registry lists 50 studies for Encephalitis, Tick-Borne across more than 10 countries. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-05-13.
Status
- Completed
- 34
- Recruiting
- 5
- Status unknown
- 5
- Not yet recruiting
- 3
- Withdrawn
- 1
- Active, not recruiting
- 1
Phase
- Phase 4
- 17
- Phase 2
- 10
- Phase 3
- 10
- Phase 1
- 2
Where
- Austria
- 13
- Germany
- 11
- Poland
- 9
- Slovenia
- 6
- Sweden
- 4
- France
- 4
Who runs them
Pfizer (19) · University Medical Centre Ljubljana (6) · Medical University of Vienna (4) · Novartis (3) · Sormland County Council, Sweden (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University Hospital, Strasbourg, France (2) · University of Surrey (1)
Studies
Recruiting first, then most recently updated. Showing 50 of 50 — search for more.
- Dexamethasone in Tick-borne EncephalitisRecruitingNCT07584525Phase 31 country
- First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.Not yet recruitingNCT07377253Phase 11 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech RepublicRecruitingNCT072740461 country
- Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in FranceRecruitingNCT071912231 country
- Tick-borne Encephalitis and Borrelial Antibodies in SerumRecruitingNCT03956446Not applicable1 country
- Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne DiseasesNot yet recruitingNCT06859619Not applicable1 country
- Primary TBE Vaccination for the ElderlyNot yet recruitingNCT04573205Phase 41 country
- Tick-borne Encephalitis Virus Research in LimousinCompletedNCT059415461 country
- Fever After Tick Bite StudyWithdrawnNCT039324481 country
- Management of Tick-borne EncephalitisCompletedNCT065932491 country
- The NOrwegian Tick-borne Encephalitis StudyActive, not recruitingNCT051380551 country
- Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in ChildrenCompletedNCT00840801Phase 32 countries
- Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and OlderCompletedNCT04648241Phase 31 country
- Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompletedNCT00460486Phase 31 country
- Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric CasesStatus unknownNCT056073941 country
- Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT RecipientsCompletedNCT01991067Phase 21 country
- Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination SchedulesCompletedNCT01562444Phase 41 country
- New Study - Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT02318069Phase 2/32 countries
- TBE Seropersistence up to 10 Years After First Booster in AdultsCompletedNCT01582698Phase 41 country
- TBE (Tick-borne Encephalitis) Vaccination in Allergic PatientsCompletedNCT02511535Phase 41 country
- Application of a TBE-Vaccine in Obese PersonsStatus unknownNCT04017052Phase 41 country
- Tick-borne Encephalitis and Possible Borrelial SerologyCompletedNCT039580581 country
- Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)CompletedNCT00894686Phase 43 countries
- Tick-borne Encephalitis and Positive Borrelial AntibodiesStatus unknownNCT02463942Not applicable1 country
- Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVacCompletedNCT01710189Phase 41 country
- Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)TerminatedNCT01031537Phase 21 country
- Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT01361776Phase 2/32 countries
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.CompletedNCT00161798Phase 21 country
- Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedNCT00161954Phase 41 country
- Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 YearsCompletedNCT00161785Phase 41 country
- Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenCompletedNCT001636181 country
- FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedNCT00161850Phase 22 countries
- Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedNCT00161746Phase 2/31 country
- Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedNCT00161824Phase 31 country
- Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 YearsCompletedNCT00161863Phase 33 countries
- TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedNCT00161967Phase 43 countries
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.CompletedNCT00161772Phase 22 countries
- TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedNCT00503529Phase 41 country
- FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedNCT00161889Phase 21 country
- FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedNCT00161876Phase 31 country
- Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)CompletedNCT00163540Phase 41 country
- An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBECompletedNCT01106482Phase 41 country
- Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis VaccinationCompletedNCT00804219Phase 41 country
- Postencephalitic Symptoms After Tick Borne EncephalitisStatus unknownNCT009415901 country
- Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus VaccineStatus unknownNCT00890422Phase 22 countries
- Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five YearsCompletedNCT00452621Phase 41 country
- Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy ChildrenCompletedNCT00311441Phase 41 country
- Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy AdultsCompletedNCT00118924Phase 11 country
- Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for AdultsCompletedNCT00311493Phase 41 country